Agios Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AGIO Nasdaq 2836 www.agios.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agios Pharmaceuticals, Inc.

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year - Jul 31st, 2026 10:17 am
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ... - Jul 30th, 2026 1:02 pm
Agios Pharmaceuticals Q2 Earnings Call Highlights - Jul 30th, 2026 8:04 am
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - Jul 30th, 2026 5:50 am
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update - Jul 30th, 2026 4:30 am
Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO) - Jul 29th, 2026 6:14 pm
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Jul 28th, 2026 2:58 am
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Jul 23rd, 2026 8:00 am
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - Jul 22nd, 2026 10:22 am
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move - Jul 21st, 2026 9:40 am
Agios scraps sickle cell drug programme on underwhelming Phase II data - Jul 21st, 2026 8:56 am
Why Is AGIO Stock Falling Today? - Jul 21st, 2026 8:09 am
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) - Jul 21st, 2026 7:39 am
Agios scraps sickle cell drug - Jul 21st, 2026 6:07 am
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - Jul 21st, 2026 5:00 am
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - Jul 10th, 2026 5:55 am
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Jul 9th, 2026 6:13 am
Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease - Jul 9th, 2026 4:13 am
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up - Jul 8th, 2026 8:32 am